Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet. 1997;349:1787 1792. 226. Ahmad J, Sha que S, Abidi SM, et al. Effect of 5-year enalapril therapy on progression of microalbuminuria and glomerular structural changes in type 1 diabetic subjects. Diabetes Res Clin Pract. 2003;60:131 138. 227. Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care. 1997;20:1576 1581. 228. Hansen KW, Klein F, Christensen PD, et al. Effects of captopril on ambulatory blood pressure, renal and cardiac function in microalbuminuric type 1 diabetic patients. Diabete Metab. 1994;20:485 493. 229. Jerums G, Allen TJ, Campbell DJ, et al. Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria. Diabet Med. 2004;21:1192 1199. 230. Jerums G, Allen TJ, Campbell DJ, et al. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis. 2001;37:890 899. 231. Muirhead N, Feagan BF, Mahon J, et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial. Curr Therapeutic Res. 1999;60:650 660. 232. O Hare P, Bilbous R, Mitchell T, et al. Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. Diabetes Care. 2000;23:1823 1829. 233. Winocour PH, Waldek S, Anderson DC. Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. Br Med J (Clin Res Ed). 1987;295:391. 234. Imai E, Chan JC, Ito S, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011;54:2978 2986. 235. Mehdi UF, Adams-Huet B, Raskin P, et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20:2641 2650. 236. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952 1961. 237. Ko GT, Tsang CC, Chan HC. Stabilization and regression of albuminuria in Chinese patients with type 2 diabetes: a one-year randomized study of valsartan versus enalapril. Adv Ther. 2005;22:155 162. 238. Rizzoni D, Porteri E, De Ciuceis C, et al. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus. Hypertension. 2005;45:659 665. 239. Schram MT, van Ittersum FJ, Spoelstra-de Man A, et al. Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and in ammation in a double-blind, randomized clinical trial. J Hum Hypertens. 2005;19: 429 437. 240. Bakris GL, Agarwal R, Chan JC, et al. Effect of nerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314:884 894. 241. van den Meiracker AH, Baggen RG, Pauli S, et al. Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J Hypertens. 2006;24:2285 2292. 242. Bjorck S, Mulec H, Johnsen SA, et al. Renal protective effect of enalapril in diabetic nephropathy. BMJ. 1992;304:339 343. 243. De Cesaris R, Ranieri G, Filitti V, et al. Effects of atenolol and enalapril on kidney function in hypertensive diabetic patients. J Cardiovasc Pharmacol. 1993;22:208 214. 244. Elving LD, Wetzels JF, van Lier HJ, et al. Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2-year prospective, randomized study. Diabetologia. 1994;37:604 609. 245. Nielsen FS, Rossing P, Gall MA, et al. Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes. 1994;43:1108 1113. 246. Nielsen FS, Rossing P, Gall MA, et al. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes. 1997;46:1182 1188. 247. Rudberg S, Osterby R, Bangstad HJ, et al. Effect of angiotensin converting enzyme inhibitor or beta blocker on glomerular structural changes in young microalbuminuric patients with Type I (insulin- dependent) diabetes mellitus. Diabetologia. 1999;42:589 595. 248. Schnack C, Hoffmann W, Hopmeier P, et al. Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. Diabetologia. 1996;39:1611 1616. 249. Stornello M, Valvo EV, Scapellato L. Persistent albuminuria in normotensive non-insulin-dependent (type II) diabetic patients: comparative effects of angiotensin-converting enzyme inhibitors and beta-adrenoceptor blockers. Clin Sci (Lond). 1992;82:19 23. 250. Guasch A, Parham M, Zayas CF, et al. Contrasting effects of calcium channel blockade versus converting enzyme inhibition on proteinuria in African Americans with non-insulin-dependent diabetes mellitus and nephropathy. J Am Soc Nephrol. 1997;8:793 798. 251. Holdaas H, Hartmann A, Lien MG, et al. Contrasting effects of lisinopril and nifedipine on albuminuria and tubular transport functions in insulin dependent diabetics with nephropathy. J Intern Med. 1991;229: 163 170. 252. Karalliedde J, Smith A, DeAngelis L, et al. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension. 2008;51:1617 1623. 253. Norgaard K, Jensen T, Christensen P, et al. A comparison of spirapril and isradipine in patients with diabetic nephropathy and hypertension. Blood Press. 1993;2:301 308. 254. O Donnell MJ, Rowe BR, Lawson N, et al. Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double-blind study. J Hum Hypertens. 1993;7:333 339. 255. Tarnow L, Sato A, Ali S, et al. Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy. Diabetes Care. 1999;22:491 494. 256. Thomas MC, Jerums G, Tsalamandris C, et al. Increased tubular organic ion clearance following chronic ACE inhibition in patients with type 1 diabetes. Kidney Int. 2005;67:2494 2499. 257. ADVANCE Collaborative Group. Effects of a xed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829 840. 258. Bakris GL, Agarwal R, Anker SD, et al. Effect of nerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383: 2219 2229. 259. Strippoli GF, Bonifati C, Craig M, et al. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006;4:CD006257. 260. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401 406. 261. Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014;174: 773 785. 262. Bangalore S, Fakheri R, Toklu B, et al. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ. 2016;352:i438. references www.kidney-international.org 263. Clase CM, Barzilay J, Gao P, et al. Acute change in glomerular ltration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes. Kidney Int. 2017;91: 683 690. 264. Bandak G, Sang Y, Gasparini A, et al. Hyperkalemia after initiating renin- angiotensin system blockade: The Stockholm Creatinine Measurements (SCREAM) Project. J Am Heart Assoc. 2017;6:e005428. 265. Jun M, Jardine MJ, Perkovic V, et al. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study. PLoS One. 2019;14: e0213192. 266. Spinowitz BS, Fishbane S, Pergola PE, et al. Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study. Clin J Am Soc Nephrol. 2019;14:798 809. 267. Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372:211 221. 268. Collard D, Brouwer TF, Peters RJG, et al. Creatinine rise during blood pressure therapy and the risk of adverse clinical outcomes in patients with type 2 diabetes mellitus. Hypertension. 2018;72:1337 1344. 269. Ku E, Ix JH, Jamerson K, et al. Acute declines in renal function during intensive BP lowering and long-term risk of death. J Am Soc Nephrol. 2018;29:2401 2408. 270. Schmidt M, Mans eld KE, Bhaskaran K, et al. Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study. BMJ. 2017;356:j791. 271. Qiao Y, Shin JI, Chen TK, et al. Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular ltration rate. JAMA Intern Med. 2020;180:718 726. 272. Ahmed AK, Kamath NS, El Kossi M, et al. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant. 2010;25:3977 3982. 273. Oxlund CS, Henriksen JE, Tarnow L, et al. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens. 2013;31:2094 2102. 274. Dhaybi OA, Bakris G. Mineralocorticoid antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2017;26:50 55. 275. Bakris GL, Agarwal R, Anker SD, et al. Design and baseline characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol. 2019;50:333 344. 276. Agarwal R, Rossignol P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2019;394:1540 1550. 277. Menne J, Farsang C, Deak L, et al. Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial. J Hypertens. 2008;26:1860 1867. 278. Tobe SW, Clase CM, Gao P, et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation. 2011;123:1098 1107. 279. Fernandez Juarez G, Luno J, Barrio V, et al. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial. Am J Kidney Dis. 2013;61:211 218. 280. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892 1903. 281. Sharma P, Blackburn RC, Parke CL, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease. Cochrane Database Syst Rev. 2011;10:CD007751. 282. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. 283. Ferrari P, Marti HP, P ster M, et al. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens. 2002;20:125 130. 284. Leon SJ, Tangri N. The use of renin-angiotensin system inhibitors in patients with chronic kidney disease. Can J Cardiol. 2019;35:1220 1227. 285. Anand V, Kshiragar AV, Navaneethan SD, et al. Direct renin inhibitors for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2013;9:CD01072. 286. Bakris GL, Oparil S, Purkayastha D, et al. Randomized study of antihypertensive ef cacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2013;15:92 100. 287. Fogari R, Mugellini A, Zoppi A, et al. Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria. Expert Opin Pharmacother. 2013;14:371 384. 288. Ohsawa M, Tamura K, Kanaoka T, et al. Addition of aliskiren to angiotensin receptor blocker improves ambulatory blood pressure pro le and cardiorenal function better than addition of benazepril in chronic kidney disease. Int J Mol Sci. 2013;14:15361 15375. 289. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204 2213. 290. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433 2446. 291. Persson F, Rossing P, Reinhard H, et al. Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial. Diabetologia. 2010;53:1576 1580. 292. Burgess E, Muirhead N, Rene de Cotret P, et al. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol. 2009;20: 893 900. 293. Ruggenenti P, Perticucci E, Cravedi P, et al. Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol. 2008;19:1213 1224. 294. Ruggenenti P, Bettinaglio P, Pinares F, et al. Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. Clin J Am Soc Nephrol. 2008;3: 1511 1525. 295. Currie G, Taylor AH, Fujita T, et al. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol. 2016;17:127. 296. Cross NB, Webster AC, Masson P, et al. Antihypertensive treatment for kidney transplant recipients. Cochrane Database Syst Rev. 2009;3: CD003598. 297. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(suppl 3):S1 S155. 298. Seeman T, Dusek J, Simankova N, et al. ESCORT trial-effects of strict control of blood pressure in pediatric renal transplant recipients- baseline characteristics of patients from a randomized controlled trial [abstract no: P-SAT456]. Pediatric Nephrology. 2013;28:1531. 299. Carpenter MA, John A, Weir MR, et al. BP, cardiovascular disease, and death in the folic acid for vascular outcome reduction in transplantation trial. J Am Soc Nephrol. 2014;25:1554 1562. 300. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative transplant study. Kidney Int. 1998;53:217 222. 301. Pagonas N, Bauer F, Seibert FS, et al. Intensive blood pressure control is associated with improved patient and graft survival after renal transplantation. Sci Rep. 2019;9:10507. 302. Beddhu S, Shen J, Cheung AK, et al. Implications of early decline in eGFR due to intensive BP control for cardiovascular outcomes in SPRINT. J Am Soc Nephrol. 2019;30:1523 1533. 303. Fernandez Fresnedo G, Franco Esteve A, Gomez Huertas E, et al. Ambulatory blood pressure monitoring in kidney transplant patients: RETENAL study. Transplant Proc. 2012;44:2601 2602. 304. Mallamaci F, Tripepi R, D Arrigo G, et al. Long-term blood pressure monitoring by of ce and 24-h ambulatory blood pressure in renal transplant patients: a longitudinal study. Nephrol Dial Transplant. 2019;34:1558 1564. 305. Tong A, Gill J, Budde K, et al. Toward establishing core outcome domains for trials in kidney transplantation: report of the Standardized Outcomes in Nephrology-Kidney Transplantation Consensus Workshops. Transplantation. 2017;101:1887 1896. 306. Tong A, Sautenet B, Poggio ED, et al. Establishing a core outcome measure for graft health: a Standardized Outcomes in Nephrology-Kidney Transplantation (SONG-Tx) Consensus Workshop report. Transplantation. 2018;102:1358 1366. 307. Alcaraz A, Oppenheimer F, Talbot-Wright R, et al. Effect of diltiazem in the prevention of acute tubular necrosis, acute rejection, and cyclosporine levels. Transplant Proc. 1991;23:2383 2384. 308. Campistol JM, Oppenheimer F, Vilardell J, et al. Interaction between ciclosporin and diltiazem in renal transplant patients. Nephron. 1991;57:241 242. www.kidney-international.org references 309. Chen SY, Li JL, Meng FH, et al. Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism a prospective, randomized, controlled study. Clin Transplant. 2013;27:E272 E281. 310. Chrysostomou A, Walker RG, Russ GR, et al. Diltiazem in renal allograft recipients receiving cyclosporine. Transplantation. 1993;55:300 304. 311. Dawidson I, Rooth P, Lu C, et al. Verapamil improves the outcome after cadaver renal transplantation. J Am Soc Nephrol. 1991;2:983 990. 312. Frei U, Harms A, Bakovic-Alt R, et al. Calcium channel blockers for kidney protection. J Cardiovasc Pharmacol. 1990;16:S11 S15. 313. Guerin C, Berthoux P, Broyet C, et al. Effects of diltiazem on arterial pressure and renal function in renal transplanted and cyclosporin A treated subjects. Results after 3 months of a prospective study. Arch Mal Coeur Vaiss. 1989;82:1223 1227 [in French]. 314. Harper SJ, Moorhouse J, Abrams K, et al. The bene cial effects of oral nifedipine on cyclosporin-treated renal transplant recipients a randomised prospective study. Transplant Int. 1996;9:115 125. 315. Ladefoged SD, Pedersen E, Hammer M, et al. In uence of diltiazem on renal function and rejection in renal allograft recipients receiving triple-drug immunosuppression: a randomized, double-blind, placebo- controlled study. Nephrol Dial Transplant. 1994;9:543 547. 316. Lehtonen S, Isoniemi H, Salmela K. A randomised placebo controlled study on initial isradipine therapy in renal transplantation: long-term results [abstract]. Nephrol Dial Transplant. 2000;15:A276. 317. Morales JM, Andres A, Prieto C, et al. Calcium antagonist treatment of recipients minimizes early cyclosporine nephrotoxicity in renal transplantation: a prospective randomized trial. Transplant Proc. 1989;21:1537 1539. 318. Morales JM, Rodriguez-Paternina E, Araque A, et al. Long-term protective effect of a calcium antagonist on renal function in hypertensive renal transplant patients on cyclosporine therapy: a 5-year prospective randomized study. Transplant Proc. 1994;26:2598 2599. 319. Patton PR, Brunson ME, Pfaff WW, et al. A preliminary report of diltiazem and ketoconazole. Their cyclosporine-sparing effect and impact on transplant outcome. Transplantation. 1994;57:889 892. 320. Pirsch JD, D Alessandro AM, Roecker EB, et al. A controlled, double-blind, randomized trial of verapamil and cyclosporine in cadaver renal transplant patients. Am J Kidney Dis. 1993;21:189 195. 321. Rahn KH, Barenbrock M, Fritschka E, et al. Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: a randomised trial. Lancet. 1999;354:1415 1420. 322. Van den Dorpel MA, Zietse R, Ijzermans JN, et al. Prophylactic isradipine treatment after kidney transplantation: a prospective double-blind placebo-controlled randomized trial. Transplant Int. 1994;7:S270 S274. 323. van Riemsdijk IC, Mulder PG, de Fijter JW, et al. Addition of isradipine (Lomir) results in a better renal function after kidney transplantation: a double-blind, randomized, placebo-controlled, multi-center study. Transplantation. 2000;70:122 126. 324. Wagner K, Albrecht S, Neumayer HH. Protective effect of the calcium antagonist diltiazem on acute kidney failure following kidney transplantation. The results of a prospective randomized study. Dtsch Med Wochenschr. 1986;111:1363 1367 [in German]. 325. Wahlberg J, Hanas E, Bergstrom C, et al. Diltiazem treatment with reduced dose of cyclosporine in renal transplant recipients. Transplant Proc. 1992;24:311 312. 326. Wilkie ME, Beer JC, Evans SJ, et al. A double-blind, randomized, placebo- controlled study of nifedipine on early renal allograft function. Nephrol Dial Transplant. 1994;9:800 804. 327. Ibrahim HN, Jackson S, Connaire J, et al. Angiotensin II blockade in kidney transplant recipients. J Am Soc Nephrol. 2013;24:320 327. 328. Philipp T, Martinez F, Geiger H, et al. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol Dial Transplant. 2010;25:967 976. 329. Salzberg DJ, Karadsheh FF, Haririan A, et al. Speci c management of anemia and hypertension in renal transplant recipients: in uence of renin-angiotensin system blockade. Am J Nephrol. 2014;39:1 7. 330. Kuypers DR, Neumayer HH, Fritsche L, et al. Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study. Transplantation. 2004;78:1204 1211. 331. Sperschneider H, Wagner C, Korn A, et al. Effect of diltiazem on concentration of cyclosporin metabolites in Sandimmune and Neoral treated kidney transplant patients. Med Klin (Munich). 1997;92:589 596 [in German]. 332. van der Schaaf MR, Hene RJ, Floor M, et al. Hypertension after renal transplantation. Calcium channel or converting enzyme blockade? Hypertension. 1995;25:77 81. 333. Venkat Raman G, Feehally J, Coates RA, et al. Renal effects of amlodipine in normotensive renal transplant recipients. Nephrol Dial Transplant. 1999;14:384 388. 334. Wilkie ME, Beer JC, Raftery MJ, et al. Effect of nifedipine on renal haemodynamics and urinary protein excretion in stable renal transplant recipients. Transplant Proc. 1993;25:612 615. 335. Makani H, Bangalore S, Romero J, et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate a meta- analysis of randomized trials. J Hypertens. 2011;29:1270 1280. 336. Schmidt M, Mans eld KE, Bhaskaran K, et al. Adherence to guidelines for creatinine and potassium monitoring and discontinuation following renin-angiotensin system blockade: a UK general practice-based cohort study. BMJ Open. 2017;7:e012818. 337. Amara AB, Sharma A, Alexander JL, et al. Randomized controlled trial: lisinopril reduces proteinuria, ammonia, and renal polypeptide tubular catabolism in patients with chronic allograft nephropathy. Transplantation. 2010;89:104 114. 338. Beckingham IJ, Woodrow G, Hinwood M, et al. A randomized placebo-controlled study of enalapril in the treatment of erythrocytosis after renal transplantation. Nephrol Dial Transplantat. 1995;10:2316 2320. 339. Glicklich D, Gordillo R, Supe K, et al. Angiotensin converting enzyme inhibitor use soon after renal transplantation: a randomized, double- blinded placebo-controlled safety study. Clin Transplant. 2011;25:843 848. 340. Gronhagen-Riska C, Fyhrquist F, Ahonen J, et al. Angiotensin I- converting enzyme inhibition after renal transplantation. Scand J Urol Nephrol Suppl. 1984;79:63 67. 341. Hernandez E, Morales JM, Andres A, et al. Usefulness and safety of treatment with captopril in posttransplant erythrocytosis. Transplantation Proc. 1995;27:2239 2241. 342. Kim IG, Bagdasaryan AR, Birukova LS, et al. The effect of enalapril on the progression of chronic allograft nephropathy. [abstract]. Nephrol Dial Transplant. 2002;17:324. 343. Knoll GA, Fergusson D, Chasse M, et al. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4:318 326. 344. Mandelbrot DA, Alberu J, Barama A, et al. Effect of ramipril on urinary protein excretion in maintenance renal transplant patients converted to sirolimus. Am J Transplant. 2015;15:3174 3184. 345. Paoletti E, Cassottana P, Amidone M, et al. ACE inhibitors and persistent left ventricular hypertrophy after renal transplantation: a randomized clinical trial. Am J Kidney Dis. 2007;50:133 142. 346. Rashtchizadeh N, Aghaeishahsavari M, Argani H, et al. Enalapril and losartan affect lipid peroxidation in renal transplant recipients with renin-angiotensin system polymorphisms. Clin Biochem. 2007;40:194 200. 347. Takahara S, Moriyama T, Kokado Y, et al. Randomized prospective study of effects of benazepril in renal transplantation: an analysis of safety and ef cacy. Clin Exper Nephrol. 2002;6:242 247. 348. Trivedi H, Lal SM. A prospective, randomized, open labeled crossover trial of fosinopril and theophylline in post renal transplant erythrocytosis. Ren Fail. 2003;25:77 86. 349. Zhang ZH, Zhang WD, Yao K. Treatment of chronic allograft nephropathy with combination of enalapril and bailing capsule. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008;28:806 809 [in Chinese]. 350. Vanrenterghem Y, Waer M, De Keyser P, et al. Controlled trial of the protective effect of dihydroergotoxine (Hydergine) on cyclosporine- associated nephrotoxicity in renal graft recipients. Transplantation Proc. 1988;20:615 617. 351. Tylicki L, Biedunkiewicz B, Chamienia A, et al. Randomized placebo- controlled study on the effects of losartan and carvedilol on albuminuria in renal transplant recipients. Transplantation. 2006;81:52 56. 352. Medeiros M, Velasquez-Jones L, Hernandez AM, et al. Randomized controlled trial of mineralocorticoid receptor blockade in children with chronic kidney allograft nephropathy. Clin J Am Soc Nephrol. 2017;12: 1291 1300. 353. Axelrod DA, Schnitzler MA, Xiao H, et al. An economic assessment of contemporary kidney transplant practice. Am J Transplant. 2018;18: 1168 1176. references www.kidney-international.org 354. Chung R, Howard K, Craig JC, et al. Economic evaluations in kidney transplantation: frequency, characteristics, and quality-a systematic review. Transplantation. 2014;97:1027 1033. 355. Wuhl E, Witte K, Soergel M, et al. Distribution of 24-h ambulatory blood pressure in children: normalized reference values and role of body dimensions. J Hypertens. 2002;21:1995 2007. 356. Lurbe E, Agabiti-Rosei E, Cruickshank JK, et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens. 2016;34:1887 1920. 357. Simonetti GD, Santoro L, Ferrarini A, et al. Systemic hypertension and proteinuria in childhood chronic renal parenchymal disease: role of antihypertensive drug management. Paediatr Drugs. 2007;9: 413 418. 358. Matteucci MC, Chinali M, Rinelli G, et al. Change in cardiac geometry and function in CKD children during strict BP control: a randomized study. Clin J Am Soc Nephrol. 2013;8:203 210. 359. Flynn JT, Daniels SR, Hayman LL, et al. Update: ambulatory blood pressure monitoring in children and adolescents: a scienti c statement from the American Heart Association. Hypertension. 2014;63:1116 1135. 360. Ku E, McCulloch CE, Warady BA, et al. Twenty-four-hour ambulatory blood pressure versus clinic blood pressure measurements and risk of adverse outcomes in children with CKD. Clin J Am Soc Nephrol. 2018;13:422 428. 361. Stergiou GS, Karpettas N, Panagiotakos DB, et al. Comparison of of ce, ambulatory and home blood pressure in children and adolescents on the basis of normalcy tables. J Hum Hypertens. 2011;25:218 223. 362. Stergiou GS, Boubouchairopoulou N, Kollias A. Accuracy of automated blood pressure measurement in children: evidence, issues, and perspectives. Hypertension. 2017;69:1000 1006. 363. Wuhl E, Hadtstein C, Mehls O, et al. Home, clinic, and ambulatory blood pressure monitoring in children with chronic renal failure. Pediatr Res. 2004;55:492 497. 364. Warady BA, Abraham AG, Schwartz GJ, et al. Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: the Chronic Kidney Disease in Children (CKiD) cohort. Am J Kidney Dis. 2015;65:878 888. 365. Stergiou G, Stambolliu E, Bountzona I, et al. Home blood pressure monitoring in children and adolescents: systematic review of evidence on clinical utility. Curr Hypertens Rep. 2019;21:64. 366. Dionne JM, Jiang S, Ng D, et al. Ambulatory blood pressure and CKD progression in the CKiD cohort [Abstract FR-PO543]. J Am Soc Nephrol. 2017;28:542. 367. Hanson CS, Gutman T, Craig JC, et al. Identifying important outcomes for young people with CKD and their caregivers: a nominal group technique study. Am J Kidney Dis. 2019;74:82 94. 368. Halbach S. Practical application of ABPM in the pediatric nephrology clinic. Pediatr Nephrol. 2020;35:2067 2076. 369. Flynn JT, Carroll MK, Ng DK, et al. Achieved clinic blood pressure level and chronic kidney disease progression in children: a report from the Chronic Kidney Disease in Children Cohort [e-pub ahead of print]. Pediatr Nephrol. https://doi.org/10.1007/s00467-020-04833-8. Accessed January 15, 2021. 370. Kogon AJ, Pierce CB, Cox C, et al. Nephrotic-range proteinuria is strongly associated with poor blood pressure control in pediatric chronic kidney disease. Kidney Int. 2014;85:938 944. 371. Flynn JT, Mitsnefes M, Pierce C, et al. Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study. Hypertension. 2008;52:631 637. 372. Hari P, Sahu J, Sinha A, et al. Effect of enalapril on glomerular ltration rate and proteinuria in children with chronic kidney disease: a randomized controlled trial. Indian Pediatr. 2013;50:923 928. 373. Seeman T, Gilik J, Vondrak K, et al. Regression of left-ventricular hypertrophy in children and adolescents with hypertension during ramipril monotherapy. Am J Hypertens. 2007;20:990 996. 374. Cheung AK, Chang TI, Cushman WC, et al. Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019;95: 1027 1036. 375. Institute of Medicine (IOM) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. In: Graham R, Mancher M, Miller Wolman D, et al., eds. Clinical Practice Guidelines We Can Trust. Washington DC: National Academies Press; 2011. 376. Schunemann HJ, Fretheim A, Oxman AD. Improving the use of research evidence in guideline development: 9. Grading evidence and recommendations. Health Res Policy Syst. 2006;4:21. 377. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. J Clin Epidemiol. 2010;63:1308 1311. 378. Hahn D, Hodson EM, Fouque D. Low protein diets for non-diabetic adults with chronic kidney disease. Cochrane Database Syst Rev. 2020;10: CD001892. 379. Palmer SC, Maggo JK, Campbell KL, et al. Dietary interventions for adults with chronic kidney disease. Cochrane Database Syst Rev. 2017;4: CD011998. 380. Heiwe S, Jacobson SH. Exercise training for adults with chronic kidney disease (Review). Cochrane Database of Syst Rev. 2011;10:CD00323. 381. Natale P, Palmer SC, Ruospo M, et al. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease. Cochrane Database Syst Rev. 2020;6:CD013165. 382. Bagga A, Sinha A, Pandey RM, et al. Antihypertensive agents for children with chronic kidney disease (Protocol). Cochrane Database of Systematic Reviews. 2014;1:CD010911. 383. Higgins JPT, Thomas J, Chandler J, eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester UK: Wiley; 2019. 384. Guyatt GH, Oxman AD, Schunemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64:380 382. 385. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008. 386. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529 536. 387. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557 560. 388. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence imprecision. J Clin Epidemiol. 2011;64:1283 1293. 389. Brunetti M, Shemilt I, Pregno S, et al. GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence. J Clin Epidemiol. 2013;66:140 150. www.kidney-international.org references